Various Diabetes Drugs Show Distinct Liver-Protective Benefits in Large Meta-Analysis
Brazil: A large network meta-analysis suggests that commonly used glucose-lowering therapies in type 2 diabetes may differ substantially in their effects on liver-related outcomes. The study found that thiazolidinediones were most strongly associated with reduced risk of hepatocellular carcinoma, glucagon-like peptide-1 (GLP-1) receptor agonists showed the greatest protection against cirrhosis decompensation, and sodium–glucose cotransporter-2 (SGLT2) inhibitors were most strongly linked with slower progression to cirrhosis.
The findings were published in Diabetes Care and led by Pedro Robson Costa Passos from the Center of Research and Drug Development (NPDM), Federal University of Ceará, Brazil, along with international collaborators. The analysis was designed to clarify whether different antihyperglycemic drug classes offer varying degrees of protection against major adverse liver outcomes in patients with type 2 diabetes, a population known to be at increased risk of progressive liver disease.
Researchers systematically reviewed evidence from PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials, covering studies published between 1946 and August 2025. Only studies involving adults with type 2 diabetes that reported associations between glucose-lowering therapies and liver outcomes were included. In total, 46 observational studies encompassing more than 7.1 million patients were analyzed.
A three-level Bayesian network meta-analysis was used to compare drug classes while accounting for differences across studies and data sources. Outcomes included hepatocellular carcinoma, cirrhosis, decompensated liver disease, variceal bleeding, hepatic encephalopathy, and liver-related mortality, with results expressed as hazard ratios and ranked according to likelihood of benefit.
The researchers reported the following findings:
- Thiazolidinediones showed the strongest association with a reduced risk of hepatocellular carcinoma among all drug classes.
- They were linked to significantly lower cancer risk compared with DPP-4 inhibitors, GLP-1 receptor agonists, insulin, and sulfonylureas.
- GLP-1 receptor agonists showed the most consistent reduction in cirrhosis decompensation across all comparisons.
- SGLT2 inhibitors were associated with the greatest protection against progression to cirrhosis compared with DPP-4 inhibitors and GLP-1 receptor agonists.
- GLP-1 receptor agonists ranked best for reducing complications such as variceal bleeding and hepatic encephalopathy.
- SGLT2 inhibitors showed the strongest association with lower liver-related mortality.
Despite these promising associations, the authors emphasized that all included studies were observational in nature, meaning that causal relationships cannot be confirmed. Differences in patient populations, treatment duration, and confounding factors may also have influenced results.
The study highlights that liver-related benefits are not uniform across antihyperglycemic drug classes. These findings suggest that drug selection in type 2 diabetes may have important implications beyond glycemic control alone. However, the authors stress that randomized clinical trials are needed to confirm whether these observed associations reflect true therapeutic effects or are driven by underlying differences in patient characteristics.
Reference:
Pedro Robson Costa Passos, Rodrigo Motta, Valbert Oliveira Costa Filho, Mariana Macambira Noronha, Roberto Cavalcante Venâncio, Guilherme Grossi Lopes Cançado, Amanda Adler, Jeremy F. Cobbold, Jeremy W. Tomlinson; Hepatic Events Prevention by Antihyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-analysis. Diabetes Care 20 May 2026; 49 (6): 1144–1153. https://doi.org/10.2337/dc26-0336
Next Story